公司资料
Immuneering 股价、新闻与催化剂
- 股票代码:
- IMRX
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
5.30 USD (+0.95%)
收盘价
最后更新: 2026年8月21日
277M USD
市值
股价为何变动
As of Aug 21, 2026, IMRX closed up 0.95% at $5.30. No new same-company headline was identified in the current news window.
公司概览
Deep Cyclic Inhibitors
Immuneering is a late-stage clinical oncology company developing Deep Cyclic Inhibitors for RAS-, RAF- and other MAPK-driven cancers. The approach is designed to produce durable pathway inhibition while limiting resistance, cachexia and treatment-related toxicity.
Atebimetinib
Atebimetinib is an oral, once-daily MEK inhibitor and Immuneering's lead candidate. The drug is designed for combination use across multiple solid tumors rather than as a narrowly targeted monotherapy.
Pancreatic Cancer Development
The global randomized MAPKeeper 301 pivotal Phase 3 trial evaluates atebimetinib with modified gemcitabine and nab-paclitaxel as first-line treatment for metastatic pancreatic cancer. The pipeline also includes additional atebimetinib combinations and preclinical programs.
未来催化剂
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。